CN203436435U - Cerebrovascular drug-eluting stent - Google Patents
Cerebrovascular drug-eluting stent Download PDFInfo
- Publication number
- CN203436435U CN203436435U CN201320384625.3U CN201320384625U CN203436435U CN 203436435 U CN203436435 U CN 203436435U CN 201320384625 U CN201320384625 U CN 201320384625U CN 203436435 U CN203436435 U CN 203436435U
- Authority
- CN
- China
- Prior art keywords
- drug
- cerebrovascular
- stent
- firebirdtm
- sinusoidal wave
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The utility model relates to a novel cerebrovascular drug-eluting stent which is formed by a metal stent platform and a drug coating. The metal stent platform is formed by a plurality of sine waveform circle basic structures and straight type connecting rods. The drug coating comprises a bottom layer and a drug carrying layer. The structure of the cerebrovascular drug-eluting stent is excellent in flexibility and adaptability, and the cerebrovascular drug-eluting stent can smoothly pass circuitous and delicate blood vessels and diseased regions of brains. Through the optimization of the design of the number of supporting bodies and the number of waveform units, the phenomena of axial contraction, radial rebound and a 'dog-bone' effect in the stent expanding process can be improved effectively. The adopted drug coating can effectively control release of the drug, has good biocompatibility and reduces the stimulation to blood vessel endothelium and inflammatory response; in addition, the drug coating can be firmly combined with the stent, the malleability is good, the phenomena that the drug coating falls off and warps do not happen in the stent stretching and warping process, and the possibility of causing long-term blood clots is reduced. The cerebrovascular drug-eluting stent can effectively prevent blood vessel intimal hyperplasia and vascular smooth muscle cell proliferation and prevent restenosis.
Description
Technical field
This novel medical instruments field that relates to, specifically, relates to a kind of novel cerebrovascular drug FirebirdTM.
Background technology
Apoplexy, claims again apoplexy, is often referred to the morbid state that rupture of blood vessel in brain or obstruction cause.It is all very high diseases of a kind of sickness rate, mortality rate and disability rate, is one of current mankind " three large killers " (cerebrovascular disease, cardiovascular disease and tumor).Approximately 3/4 disability in various degree in apoplexy survivor, brings tremendous influence and burden to patient, family and society.Neck, vertebral artery are that heart is to blood supply in brain Bi Jingzhi road.Along with the increase at age, the blood vessel wall of human body artery inevitably occurs that the atherosis arterial lumen that causes narrows down gradually, even inaccessible when serious, causes cerebral ischemia or cerebral infarction, occurs hemiplegia, aphasia, even stupor or death.
Early stage neck, vertebral artery narrowing often cause a transient ischemic attack (TIA).If the cerebral ischemia persistent period is long, degree weight, will cause brain cell necrosis.In addition, the vertebrarterial atherosclerotic plaque of neck and the thrombosis adhering to thereof can come off under the lasting impact of blood flow, directly stop up in neck, vertebral artery or larger internal artery, cause large area cerebral tissue infraction and threat to life.Generally will there is irreversible necrosis at ischemia after 6 hours and completely lose function in brain cell, now seek treatment late again.Therefore, suggestion checks and has or not caroticovertebral stenosis when having slight cerebral ischemia attack.As serious in caroticovertebral stenosis or plaque rupture, should consider cervical vertebra arterial bracket blood vessel Transluminal Angioplasty, guarantees health to remove a hidden danger.
At present, support blood vessel Transluminal Angioplasty has become a kind of very important means for the treatment of stricture of artery with superioritys such as wound are little, safe, indication is wide, postoperative complication is few.Intravascular stent is divided into bare bracket and coating stent of medicine, and through clinical verification for many years, cardiovascular bare bracket is implanted rear restenosis rate can reach 20%～40% restenosis rate, carrys out risk to Rehabilitation treatment belt.And the degradable drug stent of the cardiovascular of existing main flow can bring the probability of thrombosis at a specified future date.
Up to the present, also there is no special a kind of bracket for eluting medicament for treatment cerebrovascular stenosis, therefore, this utility model is on the one hand from optimizing the structure of support, design a kind of more effectively cerebrovascular supporting structure, avoid, when support is expanded, " dog bone " phenomenon to occur, also there is good pliability and compliance, can be smooth and easy by tortuous, very thin blood vessel and the diseased region of brain; Adopt on the other hand a kind of effective medicine coating carrier, make it to reduce the probability that causes thrombosis at a specified future date.
utility model content
To achieve these goals, this utility model adopts following technical scheme:
A FirebirdTM, this support is comprised of metal rack platform and medication coat;
Described metal rack platform is comprised of a plurality of sinusoidal wave form circle basic structure and straight type connecting rod;
Described sinusoidal wave form circle is the circulus consisting of continuously a plurality of sinusoidal wave cell cubes;
Described " sinusoidal wave cell cube " is a waveform configuration in wave-shaped ring;
Preferably, a kind of cerebrovascular drug FirebirdTM, described every group of sinusoidal wave form circle is comprised of 6 identical sinusoidal wave cell cubes;
Preferably, a kind of cerebrovascular drug FirebirdTM, described adjacent sinusoidal wave form circle forms with the crest form relative with trough;
Preferably, a kind of cerebrovascular drug FirebirdTM, described adjacent sinusoidal wave form circle is with straight type connecting rod level connection joint;
Preferably, a kind of cerebrovascular drug FirebirdTM, the length of described straight type connecting rod is less than the crest summit of sinusoidal wave cell cube to the distance of trough the lowest point;
Preferably, a kind of cerebrovascular drug FirebirdTM, is describedly connected this crest summit mutually pressed close to and trough the lowest point with trough by straight type connecting rod at interval of a pair of adjacent crest;
Preferably, a kind of cerebrovascular drug FirebirdTM, described metal rack platform adopts cochrome material to make;
Described metal rack platform is coated with medication coat;
Described medication coat comprises bottom and drug-loaded layer;
Preferably, a kind of cerebrovascular drug FirebirdTM, described bottom consists of polyacrylate;
Preferably, a kind of cerebrovascular drug FirebirdTM, described polyacrylate is nondegradable;
Preferably, a kind of cerebrovascular drug FirebirdTM, the carrier in described drug-loaded layer is fluorinated polymer;
Preferably, a kind of cerebrovascular drug FirebirdTM, described fluorinated polymer is Kynoar;
Preferably, a kind of cerebrovascular drug FirebirdTM, described fluorinated polymer is nondegradable;
Preferably, a kind of cerebrovascular drug FirebirdTM, described in the medicine stated in drug-loaded layer be rapamycin;
Preferably, a kind of cerebrovascular drug FirebirdTM, described medication coat can be coated on metal rack platform by the mode of spraying or dip-coating.
From above-mentioned technical scheme, can find out, novel cerebrovascular drug FirebirdTM in this new embodiment, designed supporting structure has superior pliability and compliance, can be smooth and easy by tortuous, very thin blood vessel and the diseased region of brain; At the design optimization of supporter number and waveform unit number, can effectively improve axial cripetura in support process of expansion, radially resilience and " dog bone " phenomenon.The medicine coating carrier adopting is fluorinated polymer, and this polymer can effectively be controlled drug release, and biocompatibility own is good, has reduced the stimulation of blood vessel endothelium and inflammatory reaction; Simultaneously can with support strong bonded, ductility is good, in support stretching distort process, without coming off, sticks up foot phenomenon, reduces the probability that causes thrombosis at a specified future date.Drug rapamycin used, can suppress the effect of cell proliferation.Therefore can effectively prevent vascellum endometrial hyperplasia and vascular smooth muscle cell proliferation.Prevent restenosis.
Accompanying drawing explanation
In order to be illustrated more clearly in this utility model embodiment or technical scheme of the prior art, to the accompanying drawing of required use in embodiment or description of the Prior Art be done to simple introduction below, obviously, these accompanying drawings are only some specific embodiment of a kind of artery of lower extremity intravascular stent of recording of the application.This use is novel include but not limited to following these.
Fig. 1 is the cross-sectional schematic of this utility model cerebrovascular drug FirebirdTM;
Fig. 2 is that metal rack platform structure of the present utility model launches schematic diagram;
Fig. 3 is medication coat structural representation of the present utility model.
The specific embodiment
Novel in order to understand better this, existing this novel 26S Proteasome Structure and Function is by reference to the accompanying drawings done simple an introduction: as shown in Figure 1, cerebrovascular drug FirebirdTM of the present utility model, this support is comprised of metal rack platform (1) and medication coat (2); Medication coat (2) is coated in metal rack platform (1) surface by the mode of spraying or dip-coating;
As shown in Figure 2, metal rack platform (1) structure is by several groups of sinusoidal wave form circles (11), and straight type connecting rod (12) forms; Sinusoidal wave form circle (11) is comprised of 6 identical sinusoidal wave cell cubes of size (111); Sinusoidal wave form circle (11) is connected by straight type connecting rod (12); At interval of a pair of adjacent crest, by straight type connecting rod, be connected this crest summit of pressing close to mutually and trough the lowest point with trough;
As shown in Figure 3, medication coat comprises bottom (21) and drug-loaded layer (22); Bottom (21), by being nondegradable polyacrylate, is coated in the surface of metal rack platform (1) by the mode of spraying or dip-coating; Drug-loaded layer (22) is comprised of rapamycin and nondegradable fluorinated polymer;
In sum, said structure of the present utility model is good pliability and compliance not only, can be smooth and easy by tortuous, very thin blood vessel and the diseased region of brain; Adopt nondegradable medicine coating carrier simultaneously, can effectively control the release of rapamycin medicine, prevent the restenosis in pathological changes site; Than biodegradable coating, the degradable risk that causes blood vessel blockage invariably.
Claims (9)
1. a cerebrovascular drug FirebirdTM, comprises metal rack platform and medication coat, it is characterized in that: described metal rack platform surface applies described medication coat, and described metal rack platform is comprised of a plurality of sinusoidal wave form circle basic structure and straight type connecting rod.
2. cerebrovascular drug FirebirdTM as claimed in claim 2, is characterized in that: described in every group, sinusoidal wave form circle is comprised of 6 identical sinusoidal wave cell cubes.
3. cerebrovascular drug FirebirdTM as claimed in claim 3, is characterized in that: adjacent described sinusoidal wave form circle forms with the crest form relative with trough.
4. cerebrovascular drug FirebirdTM as claimed in claim 4, is characterized in that: described adjacent sinusoidal wave form circle is with straight type connecting rod level connection joint.
5. cerebrovascular drug FirebirdTM as claimed in claim 5, is characterized in that: the length of described straight type connecting rod is less than the crest summit of sinusoidal wave cell cube to the distance of trough the lowest point.
6. cerebrovascular drug FirebirdTM as claimed in claim 5, is characterized in that: at interval of a pair of adjacent crest, be connected this crest summit of pressing close to mutually and trough the lowest point with trough by straight type connecting rod.
7. cerebrovascular drug FirebirdTM as claimed in claim 1, is characterized in that: described metal rack platform adopts cochrome material to make.
8. cerebrovascular drug FirebirdTM as claimed in claim 1, is characterized in that: described medication coat comprises bottom and drug-loaded layer.
9. cerebrovascular drug FirebirdTM as claimed in claim 9, is characterized in that: described bottom is nondegradable polyacrylate, and the carrier in described drug-loaded layer is nondegradable fluorinated polymer, and the medicine in described drug-loaded layer is rapamycin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320384625.3U CN203436435U (en) | 2013-07-01 | 2013-07-01 | Cerebrovascular drug-eluting stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320384625.3U CN203436435U (en) | 2013-07-01 | 2013-07-01 | Cerebrovascular drug-eluting stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203436435U true CN203436435U (en) | 2014-02-19 |
Family
ID=50087513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201320384625.3U Expired - Lifetime CN203436435U (en) | 2013-07-01 | 2013-07-01 | Cerebrovascular drug-eluting stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203436435U (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104383612A (en) * | 2014-11-04 | 2015-03-04 | 胡堃 | Vascular stent and preparation method thereof |
| CN105435314A (en) * | 2015-12-14 | 2016-03-30 | 李雷 | Preparation method of covered endovascular stent-graft |
| CN105559944A (en) * | 2015-12-14 | 2016-05-11 | 李雷 | Covered endovascular stent-graft |
| CN107155299A (en) * | 2014-06-02 | 2017-09-12 | 阿玛安斯医药私人公司 | Bioabsorbable support |
| CN108619578A (en) * | 2017-03-22 | 2018-10-09 | 华瑞（福建）生物科技有限公司 | Bracket for eluting medicament and its preparation and application |
| CN108836566A (en) * | 2018-04-23 | 2018-11-20 | 北京大学 | A kind of New-support improving dog bone effect |
| CN116712619A (en) * | 2023-04-27 | 2023-09-08 | 雅伦生物科技(北京)有限公司 | Drug coating for medical devices |
| CN116712620A (en) * | 2023-04-27 | 2023-09-08 | 雅伦生物科技(北京)有限公司 | Drug coating, drug eluting stent containing same and preparation method thereof |
-
2013
- 2013-07-01 CN CN201320384625.3U patent/CN203436435U/en not_active Expired - Lifetime
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107155299A (en) * | 2014-06-02 | 2017-09-12 | 阿玛安斯医药私人公司 | Bioabsorbable support |
| CN104383612A (en) * | 2014-11-04 | 2015-03-04 | 胡堃 | Vascular stent and preparation method thereof |
| CN106581785A (en) * | 2014-11-04 | 2017-04-26 | 华瑞（福建）生物科技有限公司 | Intravascular stent and preparation method thereof |
| CN105435314A (en) * | 2015-12-14 | 2016-03-30 | 李雷 | Preparation method of covered endovascular stent-graft |
| CN105559944A (en) * | 2015-12-14 | 2016-05-11 | 李雷 | Covered endovascular stent-graft |
| US10695164B2 (en) | 2015-12-14 | 2020-06-30 | Evans Scientific (Beijing) Co., Ltd | Covered endovascular stent-graft |
| CN108619578A (en) * | 2017-03-22 | 2018-10-09 | 华瑞（福建）生物科技有限公司 | Bracket for eluting medicament and its preparation and application |
| CN108836566A (en) * | 2018-04-23 | 2018-11-20 | 北京大学 | A kind of New-support improving dog bone effect |
| CN116712619A (en) * | 2023-04-27 | 2023-09-08 | 雅伦生物科技(北京)有限公司 | Drug coating for medical devices |
| CN116712620A (en) * | 2023-04-27 | 2023-09-08 | 雅伦生物科技(北京)有限公司 | Drug coating, drug eluting stent containing same and preparation method thereof |
| CN116712620B (en) * | 2023-04-27 | 2023-12-12 | 雅伦生物科技(北京)有限公司 | Drug coating, drug eluting stent containing same and preparation method thereof |
| CN116712619B (en) * | 2023-04-27 | 2024-01-19 | 北京信立泰医疗器械有限公司 | Drug coating for medical devices |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN203436435U (en) | Cerebrovascular drug-eluting stent | |
| JP5536637B2 (en) | Intravascular device with net system | |
| CN104853695B (en) | The bracket coating of anti-displacement micro-patterning | |
| ES2451653T3 (en) | Implantable medical device with surface erosion polyester drug supply coating | |
| CN103945796B (en) | Grid | |
| CN103230640A (en) | Medicine-carrying cutting balloon dilating catheter | |
| JP2018167066A (en) | Endoprosthesis | |
| CN203379465U (en) | Drug-carrying cutting balloon dilating catheter | |
| JP2006500996A (en) | Apparatus and method for delivering mitomycin via an eluting biocompatible implantable medical device | |
| CN105833358B (en) | Intracranial drug eluting stent system and preparation method thereof | |
| WO2011131115A1 (en) | Stent for bifurcated vessel | |
| CN106691647A (en) | Biodegradable metal intravascular stent and application thereof | |
| CN208926716U (en) | A kind of degradable blood vessel bracket with drug composite coating | |
| CN109640882B (en) | Implantable completely-bioabsorbable intravascular polymer stent | |
| CN201453427U (en) | Intracranial artery support | |
| JP2008253707A (en) | Drug-eluting stent | |
| CN206777427U (en) | A kind of complete biological absorbable blood vessel polymer support of implanted | |
| CN101239216A (en) | Novel sacculus dilating catheter | |
| JP3206584U (en) | Lumen stent | |
| CN201008589Y (en) | Cavity path bracket with super elastic force structure | |
| CN105769398A (en) | Biodegradable vascular stent based on polyhedron deformation mechanism | |
| CN210384118U (en) | Blood vessel support for arterial stenosis | |
| CN116099058A (en) | Medicine coating and preparation method thereof | |
| CN112618121B (en) | Rapamycin drug eluting carotid artery stent | |
| JP2022078154A (en) | Medicament eluting type stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: YALUN BIOTECHNOLOGY (BEIJING) Co.,Ltd. Person in charge of patentsThe principal of patent Document name: payment instructions |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20140219 |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: YALUN BIOTECHNOLOGY (BEIJING) Co.,Ltd. Person in charge of patentsThe principal of patent Document name: Notice of Termination of Patent Rights |